Biogen (NASDAQ:BIIB) issued an update on its FY 2021 earnings guidance on Thursday morning. The company provided earnings per share guidance of $17.500-$19.000 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $18.590. The company issued revenue guidance of $10.65 billion-$10.85 billion, compared to the consensus revenue estimate of $10.63 billion.Biogen also updated its FY21 guidance to $17.50-19.00 EPS.
Shares of BIIB stock traded up $3.92 during trading hours on Thursday, reaching $326.88. 57,622 shares of the stock traded hands, compared to its average volume of 1,639,858. Biogen has a 1-year low of $223.25 and a 1-year high of $468.55. The firm has a fifty day moving average of $333.47. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.12 and a quick ratio of 1.75. The firm has a market capitalization of $49.21 billion, a price-to-earnings ratio of 17.18, a PEG ratio of 1.59 and a beta of 0.44.
Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Thursday, July 22nd. The biotechnology company reported $5.68 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.55 by $1.13. Biogen had a net margin of 23.89% and a return on equity of 42.04%. The business had revenue of $2.78 billion for the quarter, compared to analyst estimates of $2.61 billion. During the same quarter in the previous year, the business earned $10.26 earnings per share. The firm’s revenue was down 24.6% compared to the same quarter last year. As a group, analysts forecast that Biogen will post 18.61 earnings per share for the current year.
In other news, Director Brian S. Posner sold 360 shares of the stock in a transaction on Friday, June 4th. The shares were sold at an average price of $274.17, for a total value of $98,701.20. Following the completion of the transaction, the director now owns 7,400 shares in the company, valued at approximately $2,028,858. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Alfred Sandrock sold 7,672 shares of the stock in a transaction on Monday, June 7th. The shares were sold at an average price of $440.00, for a total transaction of $3,375,680.00. Following the completion of the transaction, the insider now owns 2,919 shares of the company’s stock, valued at approximately $1,284,360. The disclosure for this sale can be found here. 0.54% of the stock is owned by corporate insiders.
Biogen Company Profile
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.
Further Reading: Secondary Public Offerings
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.